Evidence map›Paper›PMID 42327994›Full record

ArticleCase reports in gastrointestinal medicine2026

Delayed-Onset Hepatocellular Liver Injury Associated With Nitrofurantoin and Herbal Supplement Use: A Case Report With Multiple Potential Exposures.

Edwin Mendoza, Manas Pustake, Jeffrey Annabi, Joshua Torres, Joanna Mendez, Lakshmi Kattamuri, Benjamin Williams, Abhizith Deoker

Abstract read
In one paragraph

Article in Case reports in gastrointestinal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Edwin MendozaDepartment of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA, ttuhsc.edu.ORCID https://orcid.org/0009-0003-4992-1230
Manas PustakeDepartment of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA, ttuhsc.edu.ORCID https://orcid.org/0000-0002-3566-0389
Jeffrey AnnabiPaul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA, ttuhsc.edu.
Joshua TorresDepartment of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA, ttuhsc.edu.
Joanna MendezDepartment of Pharmacy, University Medical Center El Paso, El Paso, Texas, USA.
Lakshmi KattamuriDepartment of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA, ttuhsc.edu.
Benjamin WilliamsDepartment of Pathology, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA, ttuhsc.edu.
Abhizith DeokerDepartment of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA, ttuhsc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nitrofurantoin, a first-line antibiotic, works effectively for treating uncomplicated urinary tract infections, but it can cause severe liver damage. In the setting of concurrent supplement use, distinguishing what caused liver damage is challenging. A 57-year-old woman who had nonalcoholic fatty liver disease developed sudden jaundice after finishing her short nitrofurantoin treatment while consuming a commercial weight-loss supplement. The laboratory results demonstrated a significant liver cell damage pattern with autoimmune test results positive while liver biopsy showed nonspecific inflammation that supported drug-induced liver injury over drug-induced autoimmune such as hepatitis. The patient received intravenous N-acetylcysteine emergently after removing all suspected hepatotoxic substances from her treatment plan. N-acetylcysteine was administered empirically due to concern for progression, although its role in nonacetaminophen DILI remains uncertain. The case demonstrates that clinicians should evaluate for polysubstance-induced liver damage when patients present with multiple possible liver-damaging substances.

Indexed as

aflatoxinautoimmune hepatitis mimicBurnjarocase reportdrug-induced liver injuryliver biopsyN-acetylcysteinenitrofurantoinweight-loss supplements

Identifiers

PMID42327994
PMCPMC13282457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.